Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Crofelemer - Napo Pharmaceuticals

Drug Profile

Crofelemer - Napo Pharmaceuticals

Alternative Names: CRO-HIV; CRO-IBS; CRO-ID; CRO-PED; Fulyzaq; Mytesi; Provir; SP 303; TRN-002- Napo Pharmaceuticals; Virend

Latest Information Update: 27 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shaman Pharmaceuticals
  • Developer Napo Pharmaceuticals; Puma Biotechnology; Salix Pharmaceuticals; Shaman Pharmaceuticals; University of California at San Francisco
  • Class Antidiarrhoeals; Biopolymers; Chromans; Flavonoids; Irritable bowel syndrome therapies; Phytotherapies; Small molecules
  • Mechanism of Action Chloride channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Diarrhoea; Short bowel syndrome
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Diarrhoea
  • Phase II Irritable bowel syndrome; Short bowel syndrome
  • No development reported Inflammatory bowel diseases
  • Discontinued Herpes simplex virus infections; Influenza virus infections

Most Recent Events

  • 05 Dec 2023 Napo Pharmaceuticals completes enrolment in its phase III OnTARGET trial for Diarrhoea (Prevention, Chemotherapy-induced) in Taiwan, Serbia, Georgia, Argentina, USA (NCT04538625)
  • 04 Apr 2023 Napo Pharmaceuticals plans a clinical trial for Diarrhoea (In children)in 2023
  • 24 Mar 2023 Napo has national stage patent applications pending for crofelemer directed to treating CID
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top